Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

BACKGROUND: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for patients with treatment-refractory advanced urothelial carcinoma (aUC), however data on biomarkers of response is lacking. METHODS: We retrospectively identified all aUC patients at our institution who received EV monothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jindal, Tanya, Zhu, Xiaolin, Bose, Rohit, Kumar, Vipul, Maldonado, Edward, Deshmukh, Prianka, Shipp, Chase, Feng, Stephanie, Johnson, Michelle S., Angelidakis, Austin, Kwon, Daniel, Borno, Hala T., de Kouchkovsky, Ivan, Desai, Arpita, Aggarwal, Rahul, Fong, Lawrence, Small, Eric J., Wong, Anthony, Porten, Sima, Chou, Jonathan, Friedlander, Terence, Koshkin, Vadim S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113661/
https://www.ncbi.nlm.nih.gov/pubmed/37091148
http://dx.doi.org/10.3389/fonc.2023.1161089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113661/
https://www.ncbi.nlm.nih.gov/pubmed/37091148
http://dx.doi.org/10.3389/fonc.2023.1161089

Ejemplares similares